metonitazene metonitazene metonitazene is an analgesic compound related to etonitazene, which was first reported in 1957, and has been shown to have approximately 100 times the potency of morphine by central routes of administration, but if used orally it has been shown to have approximately 10 times the potency of morphine. metonitazenelegal statuslegal status de: anlage ii (authorized trade only, not prescriptible) uk: under psychoactive substances act us: schedule i illegal in sweden identifiers iupac name 2--n,n-diethylethanamine cas number14680-51-4 ypubchem cid53316366chemspider81407756uniia7ff4k4cwbchemical and physical dataformulac21h26n4o3molar mass382.464 g·mol−13d model (jsmol)interactive image smiles ccn(cc)ccn1c2=c(c=c(c=c2)(=o))n=c1cc3=cc=c(c=c3)oc inchi inchi=1s/c21h26n4o3/c1-4-23(5-2)12-13-24-20-11-8-17(25(26)27)15-19(20)22-21(24)14-16-6-9-18(28-3)10-7-16/h6-11,15h,4-5,12-14h2,1-3h3key:hngztlmrqtvpbh-uhfffaoysa-n its effects are similar to other opioids such as fentanyl and heroin, including analgesia, euphoria, and sleepiness. adverse effects include vomiting, and respiratory depression that can potentially be fatal. because of high dependency potential and dangerous adverse effects it has never been introduced into pharmacotherapy. legal status in the united states, metonitazene is a schedule i controlled substance under the controlled substances act. metonitazene is not controlled under the 1971 convention on psychotropic substances; however, in many countries possession or intent to sell for human consumption might be prosecuted under several analog acts.